• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 30, 2017

View Archived Issues

Stage set for Sage bets as trial year shapes up busy; SRSE, PPD readouts due

Early translational work gets the credit for Sage Therapeutics Inc.'s set of late-stage trial readouts due near term, CEO Jeff Jonas told BioWorld. "If you look back at biotech companies in general, I'm not sure I can think of another company that's had such a wealth of potential inflection points clustered together within six months, and having achieved that in such a short period of time," he said. Read More

Gemphire solid in small HoFH study, looks to shine in phase III

Enrollment in the phase IIb COBALT-1 trial of gemcabene (CI-1027) was small, due to the orphan population of homozygous familial hypercholesterolemia (HoFH), but meaningful, according to Lee Golden, chief medical officer of Gemphire Therapeutics Inc., who cited comparisons with phase II proof-of-concept studies for approved HoFH drugs Repatha (evolocumab, Amgen Inc.), Juxtapid (lomitapide, Aegerion Pharmaceuticals Inc.) and Kynamro (mipomersen, Kastle Therapeutics LLC). Read More

Bidding war sparked by Sinovac's go-private move

HONG KONG – Sinovac Biotech Ltd., China's leading vaccine maker, is in the midst of a go-private transaction that has morphed into a heated bidding war. Read More

Experts predict AI revolution to flip health care on its head

TAIPEI, Taiwan – Artificial intelligence is already changing health care, but the revolution is only just beginning, and within the coming decade it will have completely transformed the biotech industry as we know it. Read More

Other news to note

Albany Molecular Research Inc. (AMRI), of Albany, N.Y., disclosed the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the proposed acquisition of AMRI by affiliates of The Carlyle Group in Washington and GTCR LLC in Chicago. Read More

Financings

Kuros Biosciences AG, of Zurich, Switzerland, said it sold 1.15 million new shares (excluding an overallotment option of up to 200,000 shares) to existing and new investors at a price of CHF12.50 (US$13.08) per share. In total, the company raised gross proceeds of CHF14.4 million (US$15 million) that will support the market launch of lead products Magnetos, a synthetic bone graft substitute, and Neuroseal, a dural sealant, as well as certain important activities for ongoing fibrin-PTH development programs. Read More

In the clinic

Aerpio Pharmaceuticals Inc., of Cincinnati, said the first patient was dosed in its 150-patient TIME-2b phase IIb trial testing AKB-9778 in patients with moderate to severe nonproliferative diabetic retinopathy. Patients in the trial will receive AKB-9778 15 mg subcutaneously once daily, AKB-9778 15 mg twice daily, or placebo for 12 months. The primary endpoint is the percentage of patients who improve by at least two steps in Diabetic Retinopathy Severity Score. AKB-9778 is an inhibitor of the intracellular domain of VE-PTP. (See BioWorld Today, March 17, 2017.) Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe